NRBO vs. KALA, BIVI, SYBX, COCP, TCRT, LUMO, ORGS, INDP, SLGL, and MEIP
Should you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include KALA BIO (KALA), BioVie (BIVI), Synlogic (SYBX), Cocrystal Pharma (COCP), Alaunos Therapeutics (TCRT), Lumos Pharma (LUMO), Orgenesis (ORGS), Indaptus Therapeutics (INDP), Sol-Gel Technologies (SLGL), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical preparations" industry.
KALA BIO (NASDAQ:KALA) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.
24.6% of KALA BIO shares are held by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. 13.4% of KALA BIO shares are held by company insiders. Comparatively, 0.5% of NeuroBo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
KALA BIO has a beta of -1.75, meaning that its stock price is 275% less volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.23, meaning that its stock price is 123% less volatile than the S&P 500.
In the previous week, KALA BIO had 3 more articles in the media than NeuroBo Pharmaceuticals. MarketBeat recorded 4 mentions for KALA BIO and 1 mentions for NeuroBo Pharmaceuticals. KALA BIO's average media sentiment score of 0.80 beat NeuroBo Pharmaceuticals' score of -0.77 indicating that NeuroBo Pharmaceuticals is being referred to more favorably in the news media.
KALA BIO's return on equity of -90.22% beat NeuroBo Pharmaceuticals' return on equity.
NeuroBo Pharmaceuticals has lower revenue, but higher earnings than KALA BIO.
KALA BIO currently has a consensus target price of $16.50, indicating a potential upside of 151.91%. NeuroBo Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 114.59%. Given NeuroBo Pharmaceuticals' higher probable upside, research analysts clearly believe KALA BIO is more favorable than NeuroBo Pharmaceuticals.
KALA BIO received 271 more outperform votes than NeuroBo Pharmaceuticals when rated by MarketBeat users. However, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 66.67% of users gave KALA BIO an outperform vote.
Summary
KALA BIO beats NeuroBo Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get NeuroBo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroBo Pharmaceuticals Competitors List
Related Companies and Tools
